Document 3142
 DOCN  M94A3142
 TI    Does Pneumocystis carinii prophylaxis modify the clinical and biological
       AIDS presentation? Results of the Bordeaux Hospital cohort (France,
       1985-1993). The GECSA.
 DT    9412
 AU    Morlat P; Hubert JB; Chene G; Dequae L; Vimart E; Dabis F; Hopital
       Saint-Andre, INSERM U.330, Bordeaux, France.
 SO    Int Conf AIDS. 1994 Aug 7-12;10(1):144 (abstract no. PB0004). Unique
       Identifier : AIDSLINE ICA10/94369433
 AB    OBJECTIVES: To compare the clinical and immunological features at time
       of AIDS diagnosis in patients who received Pneumocystis carinii (P.c.)
       prophylaxis (P+) and in those who did not (P-). METHODS: From 1985 to
       September 1993, data on 3117 HIV-infected patients have been
       prospectively recorded in a hospital-based surveillance system. The
       study was limited to incident AIDS cases (patients included in the
       cohort before the diagnosis of AIDS). AIDS was defined according to the
       1987 CDC definition. Measurement of CD4 lymphocyte count (CD4+) was done
       at time of AIDS diagnosis. A patient was considered to have received
       P.c. prophylaxis if such treatment was reported at any visit before the
       diagnosis of the initial AIDS-related illness. RESULTS: 523 of the 1004
       AIDS cases reported were incident cases. CD4+ were measured in 396
       patients. TABULAR DATA, SEE ABSTRACT VOLUME. CONCLUSION: Mean CD4+ count
       at time of AIDS diagnosis was significantly lower (p < 0.01) in patients
       who received P.c. prophylaxis. This suggest that P.c. prophylaxis (and
       possibly the early use of zidovudine) delays the onset of the initial
       AIDS-related illness. The avaibility of a specific prophylaxis allowed a
       decrease in the occurence of P.c. pneumonia; nevertheless P.c. pneumonia
       remained frequent. In addition to research on prevention against other
       opportunistic infections, efforts should still be carried on to improve
       compliance and efficiency of the P.c. prophylaxis.
 DE    Acquired Immunodeficiency Syndrome/EPIDEMIOLOGY/IMMUNOLOGY/
       *PHYSIOPATHOLOGY  AIDS-Related Opportunistic Infections/*PREVENTION &
       CONTROL  Cohort Studies  Comparative Study  France  Human  Incidence
       Leukocyte Count  Pneumocystis carinii Infections/*PREVENTION & CONTROL
       Prospective Studies  T4 Lymphocytes/IMMUNOLOGY  Zidovudine/THERAPEUTIC
       USE  MEETING ABSTRACT

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).